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ABSTRACT 
 
Background 
Rational medicine use is essential to optimize quality of healthcare delivery and resource utilization.  
 
Objective  
To conduct a systematic review of changes in prescribing patterns in the WHO African region and 
comparison with WHO indicators in two time periods 1995-2005 and 2006-2015.  
 
Methods  
Systematic searches were conducted in PubMed, Scopus, Web of science, Africa-Wide Nipad, Africa 
Journals Online (AJOL), Google scholar and INRUD Bibliography databases to identify primary studies 
reporting prescribing indicators in Africa. This was supplemented by a manual search of retrieved references. 
We assessed the quality of studies using a 14-point scoring system modified from the Downs and Black 
checklist with inclusions of recommendations in the WHO guidelines. 
 
Results  
Forty-three studies conducted in eleven African countries were included in the overall analysis. These studies 
presented prescribing indicators based on a total 141,323 patient encounters across 572 primary care 
facilities. The results of prescribing indicators were determined as follows; average number of medicines 
prescribed per patient encounter = 3.1 (IQR 2.3- 4.8), percentage of medicines prescribed by generic name 
=68.0% (IQR 55.4-80.3), Percentage of encounters with antibiotic prescribed =46.75% (IQR 33.7-62.8), 
percentage of encounters with injection prescribed =25.0% (IQR 18.7-39.5) and the percentage of medicines 
prescribed from essential medicines list =88% (IQR 76.3-94.1). Prescribing indicators were generally worse 
in private compared with public facilities. Analysis of prescribing across two time points 1995-2005 and 
2006-2015 showed no consistent trends.  
 
Conclusions 
Prescribing indicators for the African region deviate significantly from the WHO reference targets. Increased 
collaborative efforts are urgently needed to improve medicine prescribing practices in Africa with the aim 
of enhancing the optimal utilization of scarce resources and averting negative health consequences 
 
 
Keywords: prescribing indicators, drug use indicators, pharmacoepidemiology, prescribing evaluation, 
medicine utilization studies, systematic reviews; Africa. 
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BACKGROUND 
According to the World Health Organization (WHO), more than half of all medicines are inappropriately 
prescribed, dispensed or sold with such practices deemed to be most prevalent in healthcare settings in the 
developing world where mechanisms for routine monitoring of medicines use are still in early stages of 
development [1-4]. In developing and low middle income countries, pharmaceuticals account for a high 
proportion of household and overall healthcare expenditure [5]. Improvements in the way in which 
medicines are used is important in reducing morbidity and mortality, building public confidence and 
reinforcing the credibility of any healthcare system as well as saving scarce resources [6-8]. The “wise List” 
in Stockholm, Sweden for instance, is an example of an improvement in medicine use with an essential 
medicines list (EML) with high adherence to just 200 medicines to improve physician familiarity with quality 
medicines and reduce costs in a high income country that could provide valuable lessons for developing 
countries seeking to optimize resource utilization [9]. 
 
Since the late eighties, the WHO together with the International Network for Rational Use of Drugs (INRUD) 
have been advocating  proper documentation of medicines use and have developed core drug use indicators 
in three related areas of prescribing practices, patient care and facility specific factors [10]. The drug use 
indicators are regarded as objective measures that can be extended to describe medicines usage in any health 
facility, country or an entire region. 
 
The core drug use indicators include five prescribing indicators which are meant to detail particular 
prescribing characteristics related to poly-pharmacy, antibiotic use, injection use, generic prescribing and 
adherence to the essential medicines list (EML) [10, 11]. Even though an international standard of the 
prescribing indicators has not been empirically determined, the WHO has recommended reference values 
for each of the indicators (see Table 1) [12, 13]. In 1993, the WHO published the guideline “How to 
investigate drug use at health facilities: selected drug use indicators” aimed at outlining methods for the 
collection and presentation of information on medicines use in primary health care (PHC) centers [10]. 
Subsequently, the WHO has been publishing information on global medicines usage as part of its World 
Medicines Situation reports [1, 4]. A more detailed fact book focusing mainly on medicines use at PHCs in 
developing and transitional countries was also published in 2009 [14]. The broadest review on medicines 
usage was published in 2013; this incorporates data from 900 studies covering facilities at various level of 
care in 104 countries between 1990 and 2009 [15]. For the African region, the review reported the average 
number of medicines per patient encounter to be 2.6, percentage of encounters with antibiotics prescribed as 
45.9%, percentage of encounters resulting in prescription of injection as 28.4%, percentage of medicines 
prescribed from EML to be 89.0% and percentage of medicines prescribed in generic name as 65.1% [15]. 
Despite not meeting the WHO targets, the estimates show relatively frequent prescribing from EML and of 
generic products. The high percentage of antibiotic and injection prescriptions has been attributed to disease 
burden, weak health systems and patients’ preferences. A trend analysis showed ‘little progress over time’ 
[15]. 
 
The WHO African Region is one of the six regions of the WHO and consists of 47 member states with over 
927 million inhabitants in 2013 [16]. The region faces one of the greatest disease burden compared to all 
other WHO regions. In 2013, the region’s life expectancy at birth was 58 years, the lowest among all the 
WHO regions and 10 years below that of Southeast Asia (68 years), the region with the second lowest life 
expectancy [16]. According to the 2013 Global burden of disease estimates, while their relative burdens have 
seen some decline, communicable, newborn, nutritional, and maternal causes such as diarrheal diseases, 
lower respiratory infections, and protein-energy malnutrition still remain the top drivers of health loss in 
most African countries [17]. Yet, significant epidemiological transition characterized by a growing burden 
of non-communicable diseases (NCDs) is happening creating a case of an explosive “double disease burden” 
[18]. For instance, a recent systematic review demonstrated consistent increase in prevalence of hypertension 
in Africa from 19.7% in 1990 to 27.4% in 2000 and 30.8% in 2010 [19]. Aside its enormous disease burden, 
resources for improving health delivery in Africa remain scarce. In 2013, the region’s average total health 
expenditure per capita (PPP int. $) was 222, the lowest among all WHO regions and extremely low when 
compared to Europe (2,214) and Americas (3,873) [16].  Moreover, available health system structures within 
the region suffer many deficits that hinder effective healthcare delivery. For instance, in the period 2007-
2013, the physician to population ratio (per 10,000 population) was 2.7; this was far lower than the global 
average of 13.9 [16]. According to Motie, financial and human resource challenges have hindered many 
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healthcare systems within the African region from evolving to meet the emerging healthcare demands [20]. 
The increasing emergence of non-communicable diseases is likely to further exacerbate these trends. 
 
Most health systems in Africa do not have established mechanisms for routine system-wide medicine 
monitoring and utilization. Moreover reviews of specifically designed studies are deemed to be out of date 
after three to five years or even less (Whitlock et al) [21]. This paper presents a systematic review to 
summarize available information on prescribing indicators for the WHO African region over the last two 
decades (1995-2015). Our aim was to critically appraise the quality of studies on prescribing practices in the 
Africa region and to compare the results of studies on prescribing indicators at PHCs in the African region 
against WHO recommended reference values. We also wished to understand whether there are observable 
differences in prescribing at private and public facilities in the WHO African region. To this end, we defined 
public to represent all fully government owned or quasi-governmental facilities. Private was defined to cover 
for-profit and mission health facilities. 
 
 
 
METHODS 
 
WHO prescribing indicators  
The prescribing indicators measure the performance of healthcare providers in five key areas related to the 
appropriate use of medicines (Table 1) [10]. The derivation of these indicators for any health facility (s) is 
based on an analysis of patient clinical encounters. A patient encounter is recognized to represent “the 
duration of interaction between patient and health provider. Ideally, this encounter includes a number of 
components: history taking, diagnosis process: Selection of non-pharmacological or pharmacological 
treatment, prescription (and perhaps dispensing) of treatment; and explanations about treatment and its 
adverse effects, follow-up, and prevention.” [22]. The encounters may be analyzed retrospectively using data 
from medical history records or can be analyzed prospectively as patients arrive during the period of data 
collection [10]. It is important to highlight that the determination of the core prescribing indicators does not 
require information on patients’ signs and symptoms as they provide general prescribing tendencies 
(non-disease specific). The various prescribing indicators are meant to elucidate peculiar prescribing 
characteristics relating to polypharmacy, level of antibiotic and injection use and adherence to guidelines 
relating to generic and EML prescribing [23]. 
 
Table 1: WHO prescribing indicators and recommended reference values [12, 13]. 
 
Studies Retrieval Process 
We conducted a structured review of the literature in accordance with the PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) guidelines[24]. Comprehensive searches were conducted 
in PubMed, Scopus, Web of science, Africa-Wide Nipad, Africa Journals Online (AJOL), Google scholar 
and INRUD Bibliography databases. The main key words used were “primary health care, primary health 
services, community health centres, community-based healthcare, health facilities, primary healthcare 
settings’ AND  “prescribing indicators, prescribing patterns, drug use indicators, drug utilization patterns, 
prescribing evaluation, prescribing statistics, rational prescribing, rational use of medicines, health facility 
indicators” AND  “Africa , Sub-Saharan Africa , WHO African Region”. The main limits used were 
‘humans’ and ‘English’. Additionally, we searched references of published reviews and selected papers for 
additional publications. 
 
Inclusion and Exclusion of studies 
We included only observational studies published in English in peer-reviewed Journals between 1st January 
1995 and 31st December 2015, which reported at least one WHO/INRUD core prescribing indicator or where 
these indicators were derivable from results/data presented. A study must have specified the total number of 
patient encounters involved for it to be accepted into the review. Furthermore, to eliminate potential bias, 
the review included only studies in which the sample of patient encounters were attained through a random 
sampling technique [25].   For studies with duplicate publications, the version published first or one with 
complete dataset was selected. In the case of interventional studies, we included only pre (baseline) values. 
Although, most hospital facilities provide secondary level care, in certain instances, outpatient departments 
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provide primary care services. Hence, where full description of this has been provided, studies conducted in 
such settings were included. 
 
Critical appraisal of studies 
Each Study’s quality was assessed using a 14-point scoring system modified from the Downs and Black 
checklist with inclusions of recommendations in the WHO guidelines (Box 1) [10, 26]. We awarded a one 
point value if study satisfied each criteria. If study did not meet criteria, it was awarded a zero. As studies 
may not assess all the five indicators (e.g. a study may not measure antibiotic use), the criteria were applied 
in relation to the indicator (s) assessed. In view of this, the quality grading was expressed as a percentage. 
Irrespective of the number of criteria applied, a study is considered as ‘high quality’ if it scores ≥70% of the 
total tally scores based on the applicable criteria. A score of 69-51% was regarded as ‘moderate quality’ and 
a score of ≤50% was graded as ‘low quality’.  
 
Box 1: Studies’ critical appraisal checklist. 
 
Statistical analysis 
Due to the wide heterogeneity of studies, a formal meta-analysis was not conducted. We therefore adopted 
a more descriptive approach as employed in previous reviews [14, 15]. For each WHO/INRUD prescribing 
indicator, we determined the median as well as the 25th and 75th percentiles [14]. We did not determine the 
mean values across studies as this would be unduly influenced by outliers [27]. For each prescribing 
indicator, study results were not weighted by sample size to avoid the undue influence of larger sample-sized 
studies [14]. In this case, the approach we adopted was to treat each study as a single data point with equal 
weight, without regard to sample size and variance. All computations were done electronically using 
Microsoft Excel 2015® and results of prescribing indicators were compared to the WHO’s recommended 
reference values and with previous reported values [12-15]. Statistical estimates of the difference between 
the results of prescribing indicators obtained for private and public PHCs as well as between different 
publication periods was not conducted since variance would have been greatly underestimated in such 
circumstances [14]. Sub-analysis was also conducted across different facility ownerships (private vs public) 
as well as across the studies publication periods 1995-2005 and 2006-2015. 
 
 
 
RESULTS 
 
Studies identification and retrieval  
Figure 1 outlines the schematic flow of the studies identification and inclusion process. A total of 4,208 
articles were identified by literature search. After the exclusion of duplicates and irrelevant studies based on 
titles and abstracts, 44 articles were retrieved for detailed full-text analysis. Out of the 44 studies, 41 met the 
inclusion criteria for addition to the review. Two (2) additional studies were identified through the reference 
screening bringing the total number of studies included in the review to forty-three (43) [7, 8, 22, 28-67]. 
The 43 studies included in this review (Table 2) collectively reported WHO/INRUD prescribing indicators 
based on overall analysis of 141,323 patient encounters across 572 PHCs. The PHCs included 359 (62.8%) 
public and 213 (37.2%) private facilities. We were unable to separate ‘mission-based’ and ‘business/for-
profit’ in the private facilities category as studies gave a limited description of their actitivies. About 65.1% 
(n=28) of studies were published in the period 2006-2015 whereas 34.9% (n=15) were published in the years 
1995-2005. The 43 studies included in this review were conducted in 11 countries representing 23.4% 
(11/47) of countries in the region under study. The 11 countries included Ghana (4), Nigeria (11), Tanzania 
(6), Kenya (1), Gambia (1), Zambia (1), Zimbabwe (2), South Africa (6), Ethiopia (7), Burkina Faso (2) and 
Botswana (2). Figure 1-Schematic flow diagram of studies search and retrieval process. Table 2-Descriptive 
characteristics of included studies. 
 
Figure 1: Schematic flow diagram of studies search and retrieval process.  
 
Table 2: Descriptive characteristics of included studies. 
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Quality of studies 
Overall, using the quality assessment criteria outlined, 51% of studies were graded as of high quality whereas 
42% and 7% were graded as of medium and low quality respectively. The major factors that affected quality 
grades of studies included smaller sample size, lack of adherence to WHO guidelines (especially counting 
and classification of medications) and poor reporting of study information. Around  one-third (32.6%) of 
studies included in the review involved patient encounters <600 and were deemed to be small per 
recommendations outlined in the WHO guidelines [10]. This is an important consideration as studies with 
larger sample size are more likely to present representative/generalizable results. 
 
The studies collected data either prospectively (using current patients as they present for consultation) or 
retrospectively (using past medical records). In 27 studies, data on prescribing were collected retrospectively, 
in 14 studies this was done prospectively while another 2 studies used a mix approach of collecting 
prescribing information both prospectively and retrospectively. The fact that majority of studies adopted a 
retrospective approach is quite understandable as such data are easier to collect. Nonetheless, retrospective 
analysis introduces some bias if certain information is excluded owing to poor record keeping. In the study 
by Babalola et al [8] in Nigeria for instance, records of 40 patients were excluded from the analysis because 
they had incomplete data while in the case of Massele et al [50] in Tanzania, the patient registers of three 
consecutive years were abandoned for another register because they had incomplete data. It is possible that 
the excluded information may have presented different prescribing characteristics than those reported in the 
studies. Also most retrospective analyses rely on prescription sheets and hence may exclude patients who 
are not prescribed medicines. This is likely to lead to overestimation of variables such as average number of 
medicines per patient, injection prescribing rate and antibiotic prescribing rate although EML and generic 
prescribing rates are unlikely to be affected. While studies that adopted a prospective approach may 
minimize the loss of data and deal with other limitations of retrospective assessments, they also introduce 
an observer bias (Hawthorne effect) as it is difficult to blind the health facility staff. In Nsimba et al [55] 
study in Tanzania for instance, all health staff were briefed on the study prior to prospective data collection. 
Prescribers may modify their behaviour if they know they are been investigated and as such, results derived 
this way may also not be representative of typical prescribing behaviour [10]. In the two studies that adopted 
dual prospective and retrospective analysis, no significant difference in results were observed in the two 
approaches thereby affirming to a large extent the validity of their findings [40, 56]. 
 
It is recommended that prescribing indicators are analysed over an extended period (Ideally ≥1year) to 
minimized the impact of seasonal variations in morbidity patterns, peculiarities in staffing and 
inconsistencies in medicines supply which can all impact on the patterns of medicines prescribing [10, 39]. 
However, across studies reviewed, the period over which prescribing data were collected varied widely from 
as short as 1 day to as long as 24 months. Nineteen studies reported data collection period less than 1 year 
and these are likely to be prone to seasonal variations in prescribing and may not necessarily represent usual 
trends. 
 
 
Average number of medicines prescribed per patient encounter 
Information on the number of medicines prescribed per patient encounter on average was obtained from 40 
studies covering a total patient encounter of 138,671. Among these studies, the median number of medicines 
prescribed per patient encounter was 3.1 (IQR 2.3- 4.8) (Table 3). The average number of medicines 
prescribed per patient encounter was higher for public 2.6 (IQR 2.2-4.7) than private 2.5 (IQR 2.3-3.2) 
centres. The reported average medicines prescribed per patient was higher for studies published in the period 
2006-2015 (3.5; IQR 2.2-5.6) than the period 1995-2005 (2.4; IQR 2.3-4.0). 
 
 
Percentage of medicines prescribed by generic name 
Generic prescribing rate was reported in 33 studies covering a total of 121,797 patient encounters. Among 
these studies, the generic prescribing rate was 68.0% (IQR 55.4-80.3). Public PHCs reported a higher 
percentage (68.9%; IQR 57.6-84.5) of medicines prescribed generically than private centres (61.3%; IQR 
47.7-75.7). Generic prescribing rate for studies published in the period 2006-2015 (70.4%; IQR 60.7-81.1) 
was higher than for studies published in the period 1995-2005 (64.2%; IQR 51.9-77.9). 
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Percentage of encounters with antibiotic prescribed 
Data on antibiotic prescribing rate was also retrieved from 34 studies comprising of a total of 120,422 patient 
encounters. The overall proportion of encounters resulting in the use of antibiotics was 46.8% (IQR 33.7-
62.8). Public PHCs reported lower antibiotic prescribing rate (45.0%; IQR 30.13-60.2) compared to private 
facilities (51.3%; IQR 37.5-66.6). Higher antibiotic prescribing rate was recorded among studies published 
in the period 2006-2015 (49.0%; IQR 37.8-63.1) than for those published in the period 1995-2005 (43.1%, 
IQR 33.7-61.7). 
 
 
Percentage of encounters with injection prescribed 
Injection prescribing rate was retrieved from 32 studies consisting of a total 40,096 patient encounters. The 
overall proportion of encounters resulting in the prescription of an injection was 25.0% (IQR 18.7-39.5). 
The proportion of encounters at public PHCs which resulted in the prescription of an injection was 
determined as 25.6% (IQR 14.1-44.8) while that of private facilities was 29.0% (IQR 19.0-39.5). Injection 
prescribing rate was higher across studies published in the period 2006-2015 (25.0%; IQR 17.1-41.4) 
compared to studies published in the period 1995-2005 (24.8%; IQR 18.7-37.4). 
 
 
Percentage of medicines prescribed from an essential medicines list or formulary 
A total of 27 studies involving a combined number of 101,077 medicines prescribed presented rate of use of 
EML. The overall proportion of medicines prescribed from an EML was determined as 88% (IQR 76.3-
94.1). Higher proportion of prescriptions from public centres (89.9, IQR 82.9-95.6) adhered to the use of 
EML than private centres (84.0%; IQR 69.8-91.9). EML use rate was higher among studies published in the 
period 2006-2015 (88.9%; IQR 70.8-94.0) than for the studies published within 1995-2005 (87.1%; IQR 
84.9-92.0). 
 
 
Table 3: Summary of Prescribing Indicators at PHCs within the WHO African Region. 
 
 
DISCUSSION 
 
Average number of medicines per patient encounter 
Our review showed a high number of medicines (3.1) prescribed per patient encounter. This value is higher 
than that reported by the WHO factbook for the African region (2.6) and that for the European (2.5), 
Southeast Asia (2.5) and the Americas (1.8) regions [14]. The WHO analysis was however based on a larger 
number of studies as the review was not limited to studies published in peer-reviewed journals, but included 
those reported in NGOs and Ministry of health reports and from other grey literature. On the other hand, 
although the WHO factbook and other reports have generally reported higher number of medicines 
prescribed per patient in private compared to public facilities we found the reverse with slightly higher 
number of medicines per patient in public (2.6) than private (2.5).  
 
A generally high number of medicines prescribed per patient exceeding WHO reference value may point to 
polypharmacy as an increasing problem in Africa. Many parts of the region are experiencing a changing 
epidemiological transition creating a double disease burden of both communicable and NCDs [68] and there 
is evidence that poly-pharmacy becomes more prominent when health personnel need to treat multiple 
diseases simultaneously [69, 70] . Additionally, demographic shifts in most parts of Africa is resulting in an 
increasing elderly population who are likely to suffer significant co-morbidities and need for multiple 
medications [71, 72]. In countries like Ghana, Kenya, Nigeria and Tanzania the population aged 60 and over 
is projected to increase by around 147%, 144% and 80%, respectively between 2005 and 2030 [73]. Such 
patterns may partly account for the observed higher number of medicines prescribed per patient in the period 
2006-2015 (3.5) as compared to the period 1995-2005 (2.4). Nonetheless, a number of studies reviewed 
reported very high levels of symptomatic management of cases [44, 50], and this may have contributed to 
the overall high number of medicines prescribed per patient.  
 
Excessive use of multiple medicines per patient (poly-pharmacy) is likely to result in increased risk of 
adverse drug interactions, dispensing errors and decreased patients’ knowledge of the correct doses of 
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medications. In the study in Nigeria by Uzochukwu et al [67], the percentage of patients remembering their 
dosing schedules decreased significantly as the number of medicines increased whereas Kapp et al [45] 
reported a direct correlation between the number of medicines prescribed and the occurrence of adverse 
events in South Africa. The occurrence of adverse events emanating from poly-pharmacy can create a cycle 
of health demands and costs as new treatments may be required [74]. 
 
 
Percentage of medicines prescribed by generic name Generics 
The generic prescribing rate attained in this study (68.0%) was lower than that recommended by the WHO 
(100%). This result however portrays a better generic prescribing rate than reported by the WHO factbook 
for the African region (60%) albeit based on smaller number of studies. However, the results appear lower 
when compared to values reported for the WHO’s Western Pacific region (78%), although higher than 
generic prescribing rates reported for the Eastern Mediterranean (27.7%) and Southeast Asian regions 
(48.9%) [14]. The lower generic prescribing rate observed in private than public centres is consistent with 
trends reported by the factbook and in other WHO reports [1, 14, 15]. 
 
The overall improved generic prescribing rate as documented by higher generic prescribing for the period 
2006-2015 compared to the period 1995-2005 may be due to the increasing availability of standard medicines 
as generics. For instance, over 45 top brand medications are expected to have patent expired between 2011 
and 2020 and thus likely to make generic versions readily available [75]. Once availability improves, lower 
cost becomes an incentive that could drive generic prescription. As an example; higher rates of generic 
prescribing [for proton pump inhibitors (PPIs) and statins] were seen in South Africa in 2010/2011 among 
patients enrolled into medical aid schemes receiving discounted medications [76]. In Netherlands, similar 
trends have been observed where about threefold increase in statins utilization was observed between 2000 
and 2010 despite a 58% decrease in reimbursed expenditure mainly as a result of multiple supply and demand 
measures, including a preferential pricing policy [77]. Moreover, in recent years, considerable education and 
studies demonstrating no difference in outcomes between originators and generics across a wide range of 
products and classes including antipsychotics, anti-infectives and cardiovascular medicines have been 
undertaken and these may have contributed to the increase in generic prescribing [78-81].  
 
The lower generic prescribing rates observed for private facilities may be due to the fact that prescribers in 
the private sector may perceive generic medicines as not financially rewarding as patients typically purchase 
medicines from same facilities and there may be a financial incentive to prescribe most expensive products 
[22]. Moreover, the prescribing of innovator (expensive) brands in the private sector may be due to 
prescriber’s quest to satisfy the expectations of their clients (often the - well -to do) who may falsely perceive 
the issuance of expensive (innovator) medicines as constituting ‘quality care’. Persistent prescription of 
branded (innovator) medicines is likely to result in increased treatment costs. In a study by Nwolisa et al at 
outpatient centres in Nigeria, the difference in cost between same drugs prescribed in brand names as against 
generic names were between 41.7% and 60% [71]. Nicolosi and Gray investigated the cost impact of generic 
and proprietary prescribing among chronic disease patients in South Africa and their findings indicated that 
of “all generic medicines identified 67.5% were more than 40% cheaper, per defined daily dose (DDD) per 
month, than the branded version” [72]. An analysis of facility-based medicines price data from 17 countries 
by Cameron and Laing [82], found that an average of 9-89% could be saved by switching from originator 
brands to lowest-price generic equivalents. To further improve generic prescribing diverse approaches may 
be adopted including addressing fears related to generics, thorough education of prescribers (beginning when 
they are in school or training) or in some instance the adoption of a compulsory INN prescribing policy [83, 
84]. 
 
 
Percentage of encounters with an antibiotic prescribed 
The percentage of encounters with antibiotics prescribed in this review was 46.8% which exceeds the 
reference value of <30% recommended by the WHO [12]. The antibiotic use rate in this study is however 
similar to that reported by the WHO (47%) [14]. However, it is lower when compared to estimates provided 
for the Eastern Mediterranean region (53.2%) but higher than that of the Americas (39.3%) and European 
(33.5%) regions [14]. A higher value for antibiotic use was reported for the private facilities (51.3%) than 
public facilities (45%) which does suppose that antibiotic prescribing may be more of a problem in the 
private than public sector-an observation consistent with WHO reported trends [1, 14]. 
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The higher antibiotic prescribing rate reported for the 2006-2015 period than for the 1995-2005 period may 
point to a non-improving or potentially worsening problem of antibiotic use in Africa. The overall high levels 
of antibiotic prescribing may partly be accounted for by the extensively documented high burden of 
infectious diseases within the African region. For instance, in the studies included in the review by Massele 
et al. [50] in Tanzania, Enato et al. [41] in Nigeria and Bosu and Ofori-Adjei [39] in Ghana, 58%, 38.3%, 
and 22% of conditions presented at the PHCs respectively were attributable to infectious diseases (excluding 
malaria). These high levels of reported infections are likely to contribute to high level of antibiotic 
prescribing. Additionally, in many parts of Africa, HIV/AIDS remains endemic which although does not 
require the use of antibiotics can increase the prevalence of opportunistic bacterial infections necessitating 
the use of antibiotics [53]. 
 
Not all antibiotic prescribing and use is appropriate. In a number of studies, antibiotics were reported as been 
prescribed to treat diseases like malaria, diarrhoea and RTIs (mostly viral in origin) conditions which do not 
usually require antibiotic use [40, 56, 59]. At PHCs in many parts of Africa, microbiology laboratory 
facilities are often non-existent and as such prescribers may rely mainly on their clinical judgment. While 
empirical use of antibiotics based on clinical judgment other than laboratory confirmations is permitted in 
many instances such as otitis, apparent pneumonia and cellulitis, it is well recognized that consistent use of 
antimicrobials when infection or diagnosis has not been established or fully confirmed can lead to 
overprescribing [85]. While it is recommended good practice that medicines are written for specified 
diagnosis in one study conducted in Nigeria by Isah [44], over 50% of the patients’ folders reviewed had no 
established diagnosis whereas another study conducted in Ethiopia by Desta et al. [40] reported that any 
compliant presented by patient was recorded as final diagnosis. One study investigated prescribing patterns 
across different health professionals and found higher level of antibiotic prescribing more prevalent in lower 
cadre staff like community nurses and health assistants than in medical doctors and pharmacists [8]. However 
across all the studies, higher antibiotic use were generally reported for mix of health workers (physicians, 
nurses, medical assistants etc.). Lack of in-service training was recognised as contributing to poor prescribing 
practices as demonstrated by one study in Ghana, in which the investigators reported that for the PHCs 
surveyed, none of the prescribers had received an in-service training in the preceding 5 years [39]. 
 
In addition to lack of adequate training, prevailing socio-cultural factors and demand are known to influence 
irrational antibiotics use [86]. These factors were reported by some studies to have influenced prescribing 
behaviours [40]. In private settings, prescribers are more likely to adhere to patient demand for antibiotics 
and injections for fear of losing out on customers and this may underline the higher antibiotic prescribing 
rate observed. Some studies found a correlation between patient overload and injection and antibiotic use 
[22, 64]. In many parts of Africa there are widespread reports of acute shortage of health staff, therefore in 
many instances, there is increased likelihood of personnel playing dual role of prescriber and dispenser. Such 
occurrences can be a breeding ground for irrational prescribing as no control mechanisms will be in place to 
check wrong, incorrect or poor prescribing. Dispensing prescribers are particularly worrying in the private-
for-profit sector where there may be financial incentives for over-prescribing. For instance, Trap et al found 
that PHC dispensing doctors were more likely to prescribe antibiotics than non-dispensing doctors in 
Zimbabwe [22]. Prescribers may find it more convenient and time-saving to prescribe an antibiotic rather 
than educate a patient that his condition does not require an antibiotic as it will require more lengthy 
discussion [87]. In a study in Ghana by Polage et al. [88], ninety-eight percent of physicians stated that they 
rarely order or never order tests, because of time constraints. 
 
Indiscriminate use of antibiotics backed by no diagnostic certainty can contribute to the development of drug 
resistance [85]. In one study included in this review, the researchers carried out further antibiotic sensitivity 
testing. Their findings indicated that, vaginal and endocervical isolates were always resistant to the 
commonly used antibiotics such as ampicillin and tetracycline but almost always sensitive to antibiotics like 
cefuroxime and gentamicin which were less frequently prescribed at the facilities [39]. The development of 
antibiotic drug resistance can cause significant morbidity and mortality as infectious disease rates remain 
high in the African region. High use of antibiotics is also costly and the development of resistance can further 
aggravate treatment cost by requiring the use of more powerful and expensive antibiotics which are likely to 
be unavailable in many parts of Africa. In the Bosu and Ofori-Adjei study in Ghana, antibiotics alone 
accounted for about 40% of treatment cost in patients in whom they were prescribed [39]. 
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Percentage of encounters with an injection prescribed 
The overall injection use rate determined in this study was 25.0% which exceeds the reference value 
(<20%) recommended by the WHO [12]. The WHO fact book reported an injection use rate of 27.5% which 
is a bit higher than that attained in this study [14]. The result also indicates a higher use of injectable 
medications when compared to results reported for Eastern Mediterranean (20.1%), European (17.2%) and 
West Pacific (23.2%) regions. In comparison, the study found higher use of injections at private facilities 
(29%) than at public centres (25.6%) which is also in accord with global trends reported by the WHO [1, 
14]. The similar injection prescribing rate in the periods 2006-2015 and 1995-2005 may highlight a non-
changing injection use behaviours among health personnel in the region.  
 
Widespread injection prescribing was reported across all mix of health workers (doctors, nurses, medical 
assistants etc.). Patient preference, socio-cultural beliefs have been also noted to influence prescribing 
behaviours. In a study by Massele and Mwaluko in Tanzania, it was reported that some patients walked into 
the PHC facility with their own supply of injectable medicines, syringes and needles asking for them to be 
prescribed these medicines because they believed injections were more powerful in restoring and 
maintaining health than other formulations [89]. As indicated previously, patient influences are likely to be 
felt more in the private sector where there may be a financial implication if prescribers do not adhere to 
patient demands. As the administration of injections often requires supervision by skilled health care 
providers, the frequency of prescription of injectable medications is important [90]. Excessive and 
indiscriminate use of injections can increase the risk of spreading blood-borne diseases such as hepatitis B 
and even HIV/AIDS especially in a region where infections rates remain high. Moreover, overuse of 
injections sets up a cycle of repeated visits putting pressure on healthcare staff and driving costs. 
 
 
Percentage of medicines prescribed from an essential medicines list or formulary 
The overall EML prescribing adherence of 88.0% in this study is comparable to the 87.8% reported by the 
WHO albeit lower than the optimal recommended value (100%) [13]. The EML prescribing rate presented 
in this review is higher when compared to estimates reported for other regions like the European (55.1%), 
Americas (71.4%) and the South East Asia (81%) regions [14]. The results obtained indicate that adherence 
to EML when prescribing is better at public (93.5%) that private facilities (83.95%), a pattern consistent with 
what has been reported previously by the WHO [14, 15]. 
 
The general high EML prescribing rate may be due to wider adoption of the use of EML in many countries 
as well as expanding number of medicines on various EMLs [91]. Regardless, the non-optimal use of EML 
as reported in this study can be attributed to a myriad of factors such as ineffective distribution of EML, 
inadequate sensitization among health workers and a general lack of enforcement mechanisms. In separate 
studies by Bosu and Ofori-Adjei [39] and Odusanya and Oyediran [7] conducted in Ghana and Nigeria 
respectively, all the facilities studied lacked a copy of an EML. Moreover, some studies reported that the 
main source of information for prescribers were drug representatives [39, 49]. Such sources have been 
documented to be problematic as drug companies may over-represent the efficacy of their medicines, 
discredit the efficacy of competitor brands and likely to induce prescribers to prescribe outside established 
guidelines [92, 93]. The lower EML adherence observed in private practice may be due to the fact that in 
many countries in Africa, the private sector is encouraged but not obliged to prescribe from EML as may be 
the case for public centres [53]. 
 
 
 
Limitations 
This systematic review has some limitations. Firstly, the identified studies were concentrated in a few (11 
out of 47) countries in the studied region. While a lack of research into this area in parts of Africa may have 
contributed to this; it may have also been due to the inclusion of only articles published in English and also 
the exclusion of grey literature. Around one-third (32.6%) of studies included in the review involved patient 
encounters <600 and were deemed to be small per recommendations outlined in the WHO guidelines [10]. 
This review also took the assumption that the African region is homogenous although in reality, there may 
be differences in disease burden, health system challenges, socio-cultural and political climates across 
countries which all can affect how medicines are used. Majority of the studies (74%) also collected data 
retrospectively. We consider that retrospective analysis may result in the overestimation of poly-pharmacy 
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(average number of medicines), antibiotic utilization and injection use because patients who were not given 
a prescription are likely to be excluded [25]. In our analysis we stratified results by key sector (public and 
private) but did not control for differences in prescriber characteristics. Therefore, the apparent differences 
in the prescribing indicators between the two sectors may be due to multiple factors. We assessed prescribing 
indicators at two time points and this is unlikely to reveal much about prescribing trends. Importantly, this 
review reports indicator-based studies which are unable to ascertain whether the reported prescribed 
medicines were actually taken by the patients involved. Indicator-based studies while able to identify 
medicine use problem areas, do not answer the question of rationality or appropriateness of treatment which 
may require a different methodology and analysis [23]. It is also important to reiterate that while the WHO 
proposed reference values are important, these have not been empirically determined [25]. While our review 
has analysed data on studies published over the last two decades, it is possible that some studies covered in 
grey literature may have been missed. 
 
 
Conclusion 
The values obtained in this review deviate significantly from the WHO recommended reference values. 
While our review is based on limited studies, it does highlight that some improvements in prescribing 
practices are needed. The prescribing patterns observed are reflective of population factors as well as varied 
health system challenges on the African continent. Increased collaborative efforts are therefore required to 
improve medicine prescribing practices in the region. This is necessary not only to avert negative health 
consequences but also to afford the optimal utilization of scarce resources. 
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Box 1: Critical Appraisal Checklist  
1. Objective of the study clearly described 
2. Study design or data collection methods clearly stated 
3. Participants representative of a general patient population (Ideally studies of prescribing 
indicators should involve a sample of general illness encounters representing a mix of health 
problems) 
4. Adequate sample size (WHO recommends a minimum of 600 encounters) 
5. Whether type of facility was specified (i.e. public or private) 
6.  Whether the number of facilities involved was specified 
7. Patient age/gender and other characteristics reported 
8. Whether study described how medicines were counted (WHO recommends that FDCs should 
be counted as one) 
9. Whether study defined the medicines to be regarded as antibiotic according to the 
WHO/INRUD classification if antibiotic indicator was assessed (Only affects quality in terms of 
% antibiotics use). 
10. Whether the reference essential medicines list (EML) used in the study was specified. 
Researchers may utilize the WHO model EML, facility EML or national EML as reference guide. 
11. Whether study specified the medicines regarded as injections. Ideally, routine immunizations 
should not be counted as injections (Only affects quality in terms of % of injections use). 
12. Whether the statistical method employed in analyzing the results of the study was 
appropriate and fully described. 
13. Whether the study described how missing data was handled and if any confounders 
14.  Whether the study results were discussed appropriately. For instance, if conclusion (s) were 
relevant to the findings. 
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WHO prescribing Indicator Reference Value 
Average number of medicines per encounter <2 
Percentage of medicines prescribed by generic name 100% 
Percentage of encounters with an antibiotic prescribed <30% 
Percentage of encounters with an injection prescribed <20% 
Percentage of medicines prescribed from an essential medicines list or formulary 100% 
 
Table 1: WHO prescribing indicators and reference values [12, 13] 
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Table 2: Descriptive characteristics of included studies 
 
 
No. 
 
 
Author Details 
 
Year of 
Publication 
 
 
Country  
Data  
collection 
method 
 
Data collection 
duration 
Mean  
age of  
patients 
 
Type of  
facility (s) 
 
No. of  
facilities 
 
 
Setting 
 
Prescriber type (s) 
No. of patient 
encounters 
1.  Abdella and Wabe [27]. 2012 Ethiopia Retrospective  1year n.s Public 1 Urban  Health Officers 384 
2.  Adisa et al [28]. 2015 Nigeria Prospective 3months ≥15 Public 8 Urban n.s 400 
3.  Afriyie and Tetteh [29]. 2013 Ghana Retrospective 7months n/s Public 1 urban Medical assistants, 
Doctors 
120 
4.  Afriyie et al [30]. 2015 Ghana Prospective 6months n/s Public 1 Urban Medical assistants, doctors 3127 
5.  Ahiabu et al [31]. 2015 Ghana   Retrospective 1 year                              n/s Private & 
Public 
4 (public=1, 
private=3) 
Urban Doctors, medical 
assistants 
1600 
6.  Angamo et al [32]. 2011 Ethiopia Prospective      6weeks n/s Public 4 Urban n.s 3058 
7.  Babalola et al [5]. 2011 Nigeria Retrospective 1 year 19.4 years Public 20 n/s Community health 
workers, physicians, 
health assistants, 
pharmacy technicians, 
nurses and Pharmacist  
560 
8.  Ball et al [33] 2000 Zimbabwe Prospective  n/s n/s Public 1 Urban  nurses 31 
9.  Bantie [34] 2014 Ethiopia Prospective n/s n/s Public 6 n/s n.s 600 
10.  Bexell et al. [35] 1996 Zambia  Retrospective 3months n/s Public  8 Urban Clinical officers 1167 
11.  Boonstra et al.[36] 2002 Botswana Prospective n/s 25.5 Public 30 Rural & Urban Registered nurse, Family 
nurse practitioner 
2994 
12.  Boonstra et al.[37] 2005 Botswana Prospective n.s <5 Public 30 Rural & Urban Nurses  255 
13.  Bosu and Ofori-Adjei [38] 2000 Ghana Retrospective 1 year 15 years Public 6 Rural  Doctors and medical 
assistants 
585 
14.  Desta et al. [39] 1997 Ethiopia Prospective & 
Retrospective 
Prospective 1-2 days 
Retrospective-1yr 
n/s Public 18 n/s n.s 2,340 
15.  Dippenar et al.[40] 2006 South Africa Prospective 2month n/s Public 1 Urban Doctors, nurses 1000 
16.  Enato et al.[41] 2012 Nigeria Retrospective 6 months n/s Public 1 Rural Doctors, nurses 315 
17.  Enato et al.[42] 2013 Nigeria Retrospective 1year n/s Public 3 Urban  Community health 
officers 
1440 
18.  Isah.[43] 2008 Nigeria Retrospective 1 year n/s Private 20 Rural n.s 2,510 
19.  Kapp et al.[44] 2013 South Africa Retrospective 3months 41.0 years Public 4 Urban n.s 400 
20.  Katende-Kyenda et al. [45] 2007 South Africa Retrospective 1year n.s private 9 Urban n.s 83655 
21.  Krause et al.[46] 1999 Burkina Faso Prospective  2months n/s Public  9 Rural  nurses 313 
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22.  Massele and Nsimba. [47] 1997 Tanzania Prospective 20 days n/s Public  & 
Private 
40 (public= 20, 
private=20) 
Urban n.s 1,200 
23.  Massele et al.[48] 2001 Tanzania Retrospective 14 months n/s Private 20 Rural & Urban Doctors 1,200 
24.  Massele et al.[49] 2007 Tanzania Retrospective 1 year n/s Public & 
Private 
20 (public= 10,  
Private=10) 
n/s n.s 2,000 
25.  Massele et al.[50] 2012 Tanzania prospective 3months n/s Public & 
Private 
20 (public=10, 
private=10) 
Urban Clinical officers, and other 
paramedics 
2,000 
26.  Meyer et al.[51] 2001 South Africa retrospective 1month n/s public 22 n/s nurses 1,287 
27.  Mohlala et al.[52] 2010 South Africa prospective 5months n/s private 36 Rural & Urban Doctors 276 
28.  Nsimba et al.[53] 2004 Tanzania Retrospective 1year n/s private 10 n/s n.s 600 
29.  Nsimba.[54] 2006 Tanzania Prospective n/s <5years Public 10 n/s n.s 652 
30.  Odusanya & Oyediran.[6] 2000 Nigeria Retrospective 6months n/s Public 12 n/s Community health 
officers, Public health 
nurses 
650 
31.  Olayemi et al.[55] 2006 Nigeria Prospective & 
Retrospective 
Prospective-2-3days 
Retrospective-n/s 
n/s Public 20 Rural & Urban n.s 1,560 
32.  Oyeyemi & Ogunleye.[56] 2013 Nigeria Retrospective 1year 34years Public 4 Urban Medical officer, 
community health officer, 
nurses and community 
health extension workers 
600 
33.  Phillips-Howard et al.[57] 2003 Kenya Retrospective  1year <5 Public 8 Rural n.s 9,318  
34.  Risk et al.[58]  2013 Gambia Retrospective 1 year 1.71 Public 20 Rural & Urban n.s 2,400 
35.  Savadogo et al.[59] 2014 Burkina Faso Prospective 1month <5 Public  2 Urban n.s 376 
36.  Shiferaw et al.[60] 2010 Ethiopia  Retrospective 1 year n/s Public 19 n/s n.s 731 
37.  Sisay and Mekonnen.[61] 2012 Ethiopia Retrospective  2years n.s Public 2 Urban n.s 424 
38.  Suleman  et al.[62] 2013 Nigeria Retrospective 3months n/s public 10 n/s n.s 222 
39.  Tamuno.[63] 2011 Nigeria Retrospective 1year n.s Private 10 Urban n.s 998 
40.  Trap et al.[22] 2002 Zimbabwe Retrospective <6 months n/s Private 57 urban Doctors  1,699 
41.  Truter et al.[64] 2010 South Africa Retrospective 8weeks n/s Public 1m Rural Supervised student 
trainees 
4026 
42.  Tsega et al.[65] 2012 Ethiopia Retrospective 1 year 25 years Public & 
Private 
11 (public=3, 
private=8) 
Rural & Urban n.s 600 
43.  Uzochukwu et al.[66] 2002 Nigeria Retrospective n/s n/s Public  33 n/s n.s 1,650 
n.s: not specified    
m: mobile clinic 
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Table 3: Summary of prescribing indicators at PHCs within the WHO African region 
 Prescribing Indicators 
Average number of 
medicines prescribed 
per encounter ℓ 
Percentage of 
medicines 
prescribed by 
generic name 
Percentage of 
encounters€ with an 
antibiotic prescribed 
Percentage of 
encounters€ with an 
injection prescribed 
Percentage of 
medicines prescribed 
from an essential 
medicines list 
WHO reference values 
(10,11) 
<2 100% <30 <20 100% 
Facility Type 
All 3.1 (IQR 2.3-4.8) 
n=138,671 
68.0% (IQR 55.4-
80.3) 
n=121,797 
46.8% (IQR 33.7-62.8) 
n=120,422 
25.0% (IQR 18.7-39.5) 
n=40,096 
88.0% (IQR 76.3-94.1) 
n=33140 
Publicℓ 2.6 (IQR 2.2-4.7) 
n=44,596 
68.9% (IQR 57.6-
84.5) 
n=28046 
45.0% (IQR 30.1-60.2) 
n=26,071 
 
25.6% (IQR 14.1-4.8) 
n=28,400 
89.9% (82.9-95.6) 
n=23,044 
 
Privateℓ 2.5 (IQR 2.3-3.2) 
n=92,475 
61.3% (IQR 47.7-
75.7) 
n=92,151 
51.3% (IQR 37.5-66.6) 
n=92,751 
29.0% (IQR 19.0-39.5) 
n=10,096 
84.0% (IQR 69.8-91.9) 
n=8,496 
Studies publication period 
1995-2005 2.4 (IQR 2.3-4.0) 
n=25,289 
64.2% (IQR 51.9-
77.9) 
n=13,949 
 
43.1% (IQR 33.7-61.7) 
n=15,971 
 
25.0% (IQR 17.1-41.4) 
n=14,549 
87.1% (IQR 84.9-92.0) 
n=10,324 
2006-2015 3.5 (IQR 2.2-5.6) 
n=113,382 
70.4% (60.7-81.1) 
n=107848 
49.0% (IQR 37.8-63.1) 
n=104,451 
24.8% (IQR 18.7-37.4) 
n=25,547 
88.9% (IQR 70.8-94.0) 
n=22,816 
IQR=interquartile range n=total number of patient encounters used in analysis   ℓ=excludes Ahiabu et al.[32] which did not provide 
individual results for public and private facilities. 
 
 
 
 
